Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects
Background. Benign prostatic hyperplasia (BPH) pharmacological treatment may promote a decrease in prostate vascularization and bladder neck relaxation with theoretical improvement in prostate biopsy morbidity, though never explored in the literature. Methods. Among 242 consecutive unselected patien...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2014/271304 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556711475412992 |
|---|---|
| author | Marina Zamuner Ciro Eduardo Falcone Arnaldo Amstalden Neto Tomás Bernardo Costa Moretti Luis Alberto Magna Fernandes Denardi Leonardo Oliveira Reis |
| author_facet | Marina Zamuner Ciro Eduardo Falcone Arnaldo Amstalden Neto Tomás Bernardo Costa Moretti Luis Alberto Magna Fernandes Denardi Leonardo Oliveira Reis |
| author_sort | Marina Zamuner |
| collection | DOAJ |
| description | Background. Benign prostatic hyperplasia (BPH) pharmacological treatment may promote a decrease in prostate vascularization and bladder neck relaxation with theoretical improvement in prostate biopsy morbidity, though never explored in the literature. Methods. Among 242 consecutive unselected patients who underwent prostate biopsy, after excluding those with history of prostate biopsy/surgery or using medications not for BPH, we studied 190 patients. On the 15th day after procedure patients were questioned about symptoms lasting over a week and classified according to pharmacological BPH treatment. Results. Thirty-three patients (17%) were using alpha-blocker exclusively, five (3%) 5-alpha-reductase inhibitor exclusively, twelve (6%) patients used both medications, and 140 (74%) patients used none. There was no difference in regard to age among groups (P=0.5). Postbiopsy adverse effects occurred as follows: hematuria 96 (50%), hematospermia 53 (28%), hematochezia 22 (12%), urethrorrhagia 19 (10%), fever 5 (3%), and pain 20 (10%). There was a significant negative correlation between postbiopsy hematuria and BPH pharmacological treatment with stronger correlation for combined use of 5-alpha-reductase inhibitor and alpha-blocker over 6 months (P=0.0027). Conclusion. BPH pharmacological treatment, mainly combined for at least 6 months seems to protect against prostate biopsy adverse effects. Future studies are necessary to confirm our novel results. |
| format | Article |
| id | doaj-art-e02d753da7da438cbde122936f4433c4 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-e02d753da7da438cbde122936f4433c42025-02-03T05:44:40ZengWileyAdvances in Urology1687-63691687-63772014-01-01201410.1155/2014/271304271304Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse EffectsMarina Zamuner0Ciro Eduardo Falcone1Arnaldo Amstalden Neto2Tomás Bernardo Costa Moretti3Luis Alberto Magna4Fernandes Denardi5Leonardo Oliveira Reis6Urology Division, Faculty of Medicine, Pontifical Catholic University of Campinas (PUC-Campinas), 13083-970 Campinas, SP, BrazilDr. Mario Gatti County Hospital, 13083-970 Campinas, SP, BrazilDr. Mario Gatti County Hospital, 13083-970 Campinas, SP, BrazilUrology Division, Department of Surgery, University of Campinas (UNICAMP), 13083-970 Campinas, SP, BrazilDepartment of Genetics, University of Campinas (UNICAMP), 13083-970 Campinas, SP, BrazilUrology Division, Department of Surgery, University of Campinas (UNICAMP), 13083-970 Campinas, SP, BrazilUrology Division, Faculty of Medicine, Pontifical Catholic University of Campinas (PUC-Campinas), 13083-970 Campinas, SP, BrazilBackground. Benign prostatic hyperplasia (BPH) pharmacological treatment may promote a decrease in prostate vascularization and bladder neck relaxation with theoretical improvement in prostate biopsy morbidity, though never explored in the literature. Methods. Among 242 consecutive unselected patients who underwent prostate biopsy, after excluding those with history of prostate biopsy/surgery or using medications not for BPH, we studied 190 patients. On the 15th day after procedure patients were questioned about symptoms lasting over a week and classified according to pharmacological BPH treatment. Results. Thirty-three patients (17%) were using alpha-blocker exclusively, five (3%) 5-alpha-reductase inhibitor exclusively, twelve (6%) patients used both medications, and 140 (74%) patients used none. There was no difference in regard to age among groups (P=0.5). Postbiopsy adverse effects occurred as follows: hematuria 96 (50%), hematospermia 53 (28%), hematochezia 22 (12%), urethrorrhagia 19 (10%), fever 5 (3%), and pain 20 (10%). There was a significant negative correlation between postbiopsy hematuria and BPH pharmacological treatment with stronger correlation for combined use of 5-alpha-reductase inhibitor and alpha-blocker over 6 months (P=0.0027). Conclusion. BPH pharmacological treatment, mainly combined for at least 6 months seems to protect against prostate biopsy adverse effects. Future studies are necessary to confirm our novel results.http://dx.doi.org/10.1155/2014/271304 |
| spellingShingle | Marina Zamuner Ciro Eduardo Falcone Arnaldo Amstalden Neto Tomás Bernardo Costa Moretti Luis Alberto Magna Fernandes Denardi Leonardo Oliveira Reis Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects Advances in Urology |
| title | Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects |
| title_full | Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects |
| title_fullStr | Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects |
| title_full_unstemmed | Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects |
| title_short | Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects |
| title_sort | impact of benign prostatic hyperplasia pharmacological treatment on transrectal prostate biopsy adverse effects |
| url | http://dx.doi.org/10.1155/2014/271304 |
| work_keys_str_mv | AT marinazamuner impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects AT ciroeduardofalcone impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects AT arnaldoamstaldenneto impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects AT tomasbernardocostamoretti impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects AT luisalbertomagna impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects AT fernandesdenardi impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects AT leonardooliveirareis impactofbenignprostatichyperplasiapharmacologicaltreatmentontransrectalprostatebiopsyadverseeffects |